Induction of mucosal tolerance to antigens
AssigneeIntrexon Actobiotics NV
InventorsPieter Rottiers, Veerle Snoeck
Life of this patent
Estimating the term…
Abstract
The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of Foxp3+ and/or IL-10 and/or TGF-β producing regulatory T-cells, capable of suppressing undesired immune responses toward an antigen, by oral delivery of said antigen in combination with an immunosuppressing cytokine secreting micro-organism.
Claims43
A medicament, nutraceutical, or medical food for treating and/or alleviating type I diabetes or for inducing immune tolerance to type I diabetes comprising a beta cell autoantigen in type I diabetes and an IL-10 secreting Lactococcus lactic.
A composition comprising a beta cell autoantigen in type I diabetes and an IL-10 secreting Lactococcus lactis.
A method for inducing immune tolerance to type I diabetes in a subject in need thereof comprising mucosally administering to said subject an effective amount of a composition comprising a beta cell autoantigen in type I diabetes and an IL-10 secreting Lactococcus lactic.
A method for treating type I diabetes in a subject in need thereof, comprising mucosally administering to said subject an effective amount of a composition comprising a beta cell autoantigen in type I diabetes and an IL-10 secreting Lactococcus lactis.
Dependencies are inferred from the claim text.